التفاصيل البيبلوغرافية
| العنوان: |
Composition and method for treating diabetes |
| Document Number: |
20080171704 |
| تاريخ النشر: |
July 17, 2008 |
| Appl. No: |
11/999208 |
| Application Filed: |
December 04, 2007 |
| مستخلص: |
The present invention comprises dosing regimens and formulations of islet cell neogenesis associated protein (INGAP) and INGAP Peptide. The formulation disclosed herein is shown have acceptable stability as a pharmaceutical composition. Further, the formulation is able to regenerate functional islets. |
| Inventors: |
Vinik, Aaron I. (Norfolk, VA, US); Rosenberg, Lawrence (Montreal, CA); Pittenger, Gary (Virginia Beach, VA, US); Taylor-Fishwick, David (Norfolk, VA, US); Salem, Michael (Ft. Lauderdale, FL, US); Mohrland, Scott (Plantation, FL, US) |
| Claim: |
1. A method of regenerating functional alpha or beta cells in the islets of Langerhans of a non-rodent mammal comprising administration of an effective amount of a peptide comprising Seq ID No. 3. |
| Claim: |
2. The method of claim 1 wherein the normal biofeedback mechanisms for insulin regulation are maintained. |
| Claim: |
3. The method according to claim 2 wherein the pharmaceutical composition comprises from about 0.1 mg to about 300 mg of the polypeptide. |
| Claim: |
4. The method according to claim 2 wherein the pharmaceutical composition comprises from about 5 mg to about 150 mg of the polypeptide. |
| Claim: |
5. The method of claim 2 wherein the administration is at a frequency selected from the group consisting of daily, twice daily, three times daily, weekly, biweekly, monthly, continuous infusion and combinations thereof. |
| Claim: |
6. The method of claim 2 wherein the pharmaceutical composition is administered for a period of at least 30 days. |
| Claim: |
7. A method of increasing beta cell mass in the islets of Langerhans of a non-rodent mammal comprising administration of an effective amount of a peptide comprising Seq ID No. 3. |
| Claim: |
8. The method of claim 6 wherein the normal biofeedback mechanisms for insulin regulation are maintained. |
| Claim: |
9. The method according to claim 6 wherein the pharmaceutical composition comprises from about 0.1 mg to about 300 mg of the polypeptide. |
| Claim: |
10. The method according to claim 6 wherein the pharmaceutical composition comprises from about 5 mg to about 150 mg of the polypeptide. |
| Claim: |
11. The method of claim 6 wherein the administration is at a frequency selected from the group consisting of daily, twice daily, three times daily, weekly, biweekly, monthly, continuous infusion and combinations thereof. |
| Claim: |
12. The method of claim 6 wherein the pharmaceutical composition is administered for a period of at least 30 days. |
| Claim: |
13. A method of establishing normal physiological glucose regulation in a mammal in need of such a treatment comprising administering to the mammal a therapeutically effective amount of a peptide comprising Seq ID No. 3. |
| Claim: |
14. The method according to claim 13 wherein the pharmaceutical composition comprises from about 0.1 mg to about 300 mg of the polypeptide. |
| Claim: |
15. The method according to claim 13 wherein the pharmaceutical composition comprises from about 5 mg to about 150 mg of the polypeptide. |
| Claim: |
16. The method of claim 13 wherein the administration is at a frequency selected from the group consisting of daily, twice daily, three times daily, weekly, biweekly, monthly, continuous infusion and combinations thereof. |
| Claim: |
17. The method of claim 13 wherein the pharmaceutical composition is administered for a period of at least 30 days. |
| Current U.S. Class: |
514/14 |
| Current International Class: |
61; 61 |
| رقم الانضمام: |
edspap.20080171704 |
| قاعدة البيانات: |
USPTO Patent Applications |
